OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear

805 Projects | 558 Researchers | $380,393,824 Invested

2025

Vesper Bio ApS

Mads Fuglsang Kjølby

Open-label multiple dosing study in asymptomatic GRN-Frontotemporal dementia patients to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VES001.

  • Funding Amount: $2,549,203
  • Organization Type:
  • Program: Drug Discovery
  • Target: Neuronal Degeneration
  • Status: Active

2025

The University of Texas Southwestern Medical Center at Dallas

Marc Diamond, MD

AAV-mediated clearance of tau aggregates in vivo

  • Funding Amount: $600,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Active

2025

University of Illinois at Chicago

Steven Ackerman, PhD

Development of novel CCR3 chemokine receptor peptide and small molecule functionally selective biased antagonists to treat neuroinflammation in Alzheimer’s disease.

  • Funding Amount: $599,515
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Active

2025

Monash University

Joanne Ryan, PhD

Leveraging a large scale randomized clinical trial to determine whether statins can prevent Alzheimer’s Disease neuropathology and dementia

  • Funding Amount: $424,461
  • Organization Type:
  • Program: Prevention
  • Target: Vascular
  • Status: Active

2025

Beth Israel Deaconess Medical Center

Chenxi Qiu, PhD

A new therapeutic antibody for Frontotemporal Dementia

  • Funding Amount: $349,590
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Active

2025

University of Pennsylvania

James Shorter, PhD

Defining oligonucleotide therapeutics that reverse FUS proteinopathy

  • Funding Amount: $350,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Proteostasis
  • Status: Active

2025

Emory University

Thomas Kukar, PhD

Development of a granulin biologic to treat progranulin deficient FTD.

  • Funding Amount: $349,890
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Proteostasis
  • Status: Active

2025

Stanford University

Giuseppe Barisano, MD, PhD

Assessing the diagnostic and prognostic value of perivascular spaces imaging in cognitive impairment and dementia through a novel fully-automated robust algorithm

  • Funding Amount: $128,500
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Vascular
  • Status: Active

2025

Foundation for the National Institutes of Health, Inc.

Tatiana Lagos , MBA

Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression

  • Funding Amount: $50,000
  • Organization Type:
  • Program: Biomarkers
  • Target: Neuronal Degeneration
  • Status: Active

2025

Circular Genomics Inc

Nikolaos Mellios, MD, PhD

Alzheimer’s disease specificity and sensitivity analyses of circRNA blood biomarkers

  • Funding Amount: $250,000
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active
View More